Manganese Chloride

DRUG6 trials

Sponsors

Chinese PLA General Hospital

Conditions

Biliary Tract Cancer (BTC)LymphomaOvarian CancerPancreatic CancerSolid Tumor

Phase 1

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Chinese PLA General HospitalPancreatic Cancer

Start: 2019-03-01End: 2022-03-31Target: 50Updated: 2020-12-23

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Chinese PLA General HospitalLymphoma, Solid Tumor

Start: 2018-11-01End: 2020-05-31Target: 20Updated: 2019-08-28

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Chinese PLA General HospitalBiliary Tract Cancer (BTC)

Start: 2019-03-01End: 2021-08-31Target: 20Updated: 2019-07-09

An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma

Chinese PLA General HospitalLymphoma, Solid Tumor

Start: 2021-05-06End: 2023-05-31Target: 10Updated: 2021-05-05

Phase 2

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

CompletedNCT03989336

Chinese PLA General HospitalOvarian Cancer

Start: 2020-12-23End: 2023-12-10Updated: 2024-07-15

Phase 3

A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer

RecruitingNCT07822646

Chinese PLA General HospitalOvarian Cancer

Start: 2026-10-12End: 2030-12-20Target: 120Updated: 2026-09-16

Related Papers

Combined regimen of inhalable STING agonist plus chemoimmunotherapy in platinum-resistant or platinum-refratory ovarian cancer: A randomized, open-label, phase II trial.

Journal of Clinical Oncology2020-05-201 citations